OSCEOLA, WI (August 27, 2013) – Pharmasan Labs has been honored twice this summer for research to improve sensitivity in Lyme disease testing.
An abstract submitted by Chenggang Jin, MD, PhD, Head of Immunology at Pharmasan Labs, was selected by the American Association for Clinical Chemistry (AACC) for a Best Abstract Award. The AACC’s Clinical Translational Science (CTS) division conferred the award on Dr. Jin’s abstract entitled “Development and Validation of a Novel IFN-gamma ELISPOT Assay for Sensitive and Spe cific Detection of Antigen-Specific T Cell Response to Borrelia burgdorferi.” Dr. Jin received a prize award of $500 during the Pediatric, Industry and CTS Combined Division Annual Meeting on July 29, 2013 in Houston.
The abstract was also selected for presentation at the 13th International Conference on Lyme Borreliosis and Other Tick-Bourne Diseases held in Boston August 18-21, 2013.
Dr. Jin’s research contributed to the development of Pharmasan Labs’ iSpot Lyme test, a highly sensitive T cell-based Lyme ELISpot assay validated for the diagnosis of Lyme. By measuring T cell activity, iSpot Lyme accurately detects Lyme in 84 percent of cases and avoids false positives in 94 percent of cases, making it one of the most reliable and sensitive Lyme test available.
AACC is an international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry and related disciplines. Founded in 1948, the society has over 8,000 members and is headquartered in Washington, DC.
The International Conference on Lyme Borreliosis and other Tick Borne Diseases (ICLB) is one of the preeminent conferences in the world for clinical, epidemiological, and pathogenetic studies of tick-borne diseases. The first conference was held in November 1983, at Yale University, and focused on Lyme borreliosis, which had recently been identified as an Ixodes sptick-transmitted spirochetal infection. Since then, the conference has been held every two to three years alternating between sites in the United States and in Europe.
About Pharmasan Labs, Inc.
Pharmasan Labs’ comprehensive test menu and wide-ranging services are tailored to support the needs of research institutions and healthcare businesses, including their practitioners and patients. Pharmasan Labs, Inc. is certified by the Clinical Laboratory Improvement Amendments program (CLIA ID# 52D0914898) and New York State Department of Health (PFI# 7426). Pharmasan Labs is a partner company to NeuroScience, Inc. For more information: www.pharmasan.com.
About NeuroScience, Inc.
NeuroScience is committed to delivering personalized health care solutions. In conjunction with Pharmasan Labs, Inc., NeuroScience provides licensed health care providers with integrative clinical assessments and proprietary nutraceuticals to identify and target neurological and hormonal imbalances. Through its Assess & Address™ approach, NeuroScience empowers forward-thinking clinicians to better understand each patient’s unique biochemistry, and guide him or her toward optimal health. For more information: www.neuroscienceinc.com.